Cover Image
市場調查報告書

膽固醇酯傳輸蛋白質 (脂質傳輸蛋白質,CETP) - 開發中產品分析

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 358691
出版日期 內容資訊 英文 58 Pages
訂單完成後即時交付
價格
Back to Top
膽固醇酯傳輸蛋白質 (脂質傳輸蛋白質,CETP) - 開發中產品分析 Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Pipeline Review, H2 2016
出版日期: 2016年09月14日 內容資訊: 英文 58 Pages
簡介

膽固醇酯傳輸蛋白質 (CETP) ,又稱為血漿脂質傳輸蛋白質,是促進膽固醇酯的傳輸的血漿蛋白質。

本報告提供膽固醇酯傳輸蛋白質 (脂質傳輸蛋白質,CETP)的開發情形調查分析,開發中產品的概要,臨床實驗的各階段的產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等系統性資訊。

目錄

簡介

概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各適應症

開發中產品的概要

  • 後期階段的產品
  • 初期階段的產品

開發中的產品:各企業

開發中的產品:各大學/研究機關

治療藥的評估

  • 各單劑/聯合治療
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Chong Kun Dang Pharmaceutical Corp.
  • Kowa Company, Ltd.
  • Merck & Co., Inc.
  • Pfizer Inc.

藥物簡介

暫停的計劃

開發中止的產品

最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0525TDB

Summary

Global Markets Direct's, 'Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Pipeline Review, H2 2016', provides in depth analysis on Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted pipeline therapeutics.

The report provides comprehensive information on the Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP)
  • The report reviews Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) Overview
  • Therapeutics Development
    • Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Products under Development by Stage of Development
    • Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Products under Development by Therapy Area
    • Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Products under Development by Indication
  • Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Products under Development by Companies
  • Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Products under Development by Universities/Institutes
  • Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Companies Involved in Therapeutics Development
    • Amgen Inc.
    • Bristol-Myers Squibb Company
    • Chong Kun Dang Pharmaceutical Corp.
    • Japan Tobacco Inc.
    • Kowa Company, Ltd.
    • Merck & Co., Inc.
    • Pfizer Inc.
  • Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Drug Profiles
    • AMG-899 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • anacetrapib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BMS-795311 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CKD-519 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dalcetrapib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HL-16 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • K-312 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PF-04445597 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Dormant Projects
  • Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Discontinued Products
  • Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Featured News & Press Releases
    • Aug 23, 2016: DalCor Announces Opening of International Trial Sites for Its Dal-GenE Phase 3 Cardiovascular Outcomes Trial
    • Jul 18, 2016: DalCor Dalcetrapib Demonstrates Genotype-Dependent Effects on Cholesterol Efflux and Inflammation in Data Published by The Montreal Heart Institute in Circulation: Cardiovascular Genetics
    • Apr 26, 2016: DalCor Randomizes First Patient in the DalGenE Phase 3 Cardiovascular Outcomes Trial
    • Nov 13, 2015: Merck Provides Update on REVEAL Outcomes Study
    • Jun 08, 2015: DalCor Pharma licenses a late-stage investigational cardiovascular drug following major scientific discovery
    • Jun 03, 2015: Dezima Pharma's CETP Inhibitor, TA-8995, Phase 2b (TULIP) Study Results Published in The Lancet
    • Jan 12, 2015: A World First - Discovery of a personalized therapy for cardiovascular disease
    • Nov 13, 2014: Dezima Pharma Announces Complete Enrolment of CETP Inhibitor TA-8995 Study in Subjects With Isolated, Elevated Lipoprotein(a) Levels
    • Aug 29, 2014: Dezima Reports Positive Results in its Phase 2b TULIP Trial with CETP Inhibitor TA-8995 in Dyslipidemia
    • Jul 08, 2014: Dezima Pharma extends clinical development program for its CETP Inhibitor TA-8995
    • Jan 13, 2014: Dezima Pharma Completes Patient Enrolment for TULIP Phase 2B Study with CETP Inhibitor TA-8995
    • Aug 29, 2013: Dezima Pharma initiates Phase 2b TULIP study on CETP inhibitor program DEZ-001
    • Nov 05, 2012: Roche's Dalcetrapib Increases HDL Levels But Fails To Reduce Risk Of Cardiovascular Events, Study Finds
    • Aug 26, 2012: Merck Provides Update On Anacetrapib Development Program
    • May 07, 2012: Roche Provides Update On Phase III Study Of Dalcetrapib
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Pipeline by Amgen Inc., H2 2016
  • Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2016
  • Pipeline by Japan Tobacco Inc., H2 2016
  • Pipeline by Kowa Company, Ltd., H2 2016
  • Pipeline by Merck & Co., Inc., H2 2016
  • Pipeline by Pfizer Inc., H2 2016
  • Dormant Projects, H2 2016
  • Discontinued Products, H2 2016
  • Discontinued Products (Contd..1), H2 2016
  • Discontinued Products (Contd..2), H2 2016

List of Figures

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
Back to Top